Meeting attendance totaled 12,490, up 5.3 percent over the 2014 total.
Company limits US launch based on surgeon equipment.
He chose to keep the Tesla, rather than taking $30,000 in cash,
Surgeons reported positive outcomes using excimer laser-based methods.
Optos demonstrated its California widefield retinal imager, while Carl Zeiss Meditec showed its latest HFA3 perimeter with Liquid Lens technology.
Abbott Medical Optics launched the Compact INTUITIV, while DORC announced FDA approval of its EVA system.
Some surgeons showed slightly improved visual outcomes compared with conventional ultrasonic phaco.
EDOF and low add multifocal IOLs are increasing the demand for PC-IOLs.
High interest was shown in the Calhoun Vision LAL.
Glaucoma treatment represents a growing percentage of cataract surgeons' practice.
Presentations included updates from PowerVision, Sharklet, and Mynosys.
Company expects decision on lifitegrast by October 25.
Keynote speaker questioned shunts as first-line treatment in glaucoma patients due to side effects.
PDGF inhibitor has generated excitement as a treatment for wet AMD since the release of Phase II data in 2012.
Company reported sales of more than 70,000 iStent devices globally through the end of 2014.
Providers will see increases of 0.5 percent each year from 2015 through 2019.
Congress is moving quickly on its proposed 21st Century Cures Act. Meanwhile, a drug maker has sued the FDA for the right to discuss off-label uses of its product.
LinCor says its goal is to help reduce the tremendous shortage of donor corneas globally.
The company founder was reinstated as chief executive officer on May 1.
You are not currently logged in.
©2017 Market Scope
Lost your Password